[基础医学]2012第54届美国血液年会ASH进展.ppt

[基础医学]2012第54届美国血液年会ASH进展.ppt

  1. 1、本文档共48页,可阅读全部内容。
  2. 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
[基础医学]2012第54届美国血液年会ASH进展

* p1924 * * 1926 * * * Best standard therapy for cGVHD:Clinical trial Agent Nilotinib MSC Alefacept IL-2 Bortezomib Pomalidomide Imatinib vs ritux Montelukast(白三) Rituximab ECP Ofatumumab SIRO vs SIRO/CSA Setting 2nd line 2nd line 2nd line 2nd line 2nd line 2nd line Skin sclerosis BOS 1st line 1st line 1st line 1st line Design Phase 1 Phase 1 Phase 1/2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 2 Phase 1/2 Phase 2/3 Institution Stanford.CA Karolinska.Sweden Jerusalem.Israel DFCI.Massachusetts Baylor.Texas NCI.Maryland US cGVHDConsortium NCI.Maryland Nantes.France Therakos,multicenter Moffitt,Florida BMT CTN.USA ClnicalTrials .gov.accessed Nov.30.2012 * Are we making progress in GVHD prophylaxis and treatment? Clear progress is made in clinical characterization,standardization and multicenter collaboration Acute GVHD -Calcineurin-inhibitor prophylaxis a gold standard,new strategies - Steroids standard front-line therapy,no second-line standard Chronic GVHD - No standard prophylaxis,ATG, TCD, High-Cy show promise - Steroids standard front-line therapy,no second-line standard Emerging biology-based agents Advances in biomarkers and biology will likely lead to individualized and better treatments in the near future An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future GVHD Following Related Donor HSCT Abstract 463: Andrew C. Harris, University of Michigan, Ann Arbor, MI Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI Pediatric Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI Objective: We have now evaluated whether a combination of pre-HCT clinical characteristics and GVHD biomarkers measured early post-HCT can predict the future occurrence of GVHD with sufficient accuracy and lead time to facilitate the preemptive treatment of a large majority of patients at high risk prior to the onset of GVHD symptoms. Methods: 393 pat

文档评论(0)

qiwqpu54 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档